UBS analyst Chen Chen upgraded Wuxi Apptec from Neutral to Buy, raising the price target from HK$40.10 to HK$70.40, citing signs of recovery in the CRO sector and growth in revenue and backlog. Despite disappointing Q3 results, the outlook is bolstered by potential biopharma funding from recent Federal Reserve rate cuts and Chinese economic stimulus. UBS has also revised its revenue, margin, and EPS estimates for 2025-2028, reflecting a more optimistic financial forecast for the company.